Patents by Inventor Keren-Or AMAR

Keren-Or AMAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF
    Publication number: 20230212261
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Application
    Filed: December 20, 2022
    Publication date: July 6, 2023
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David NAOR, Lora ESHKAR-SEBBAN, Keren-Or AMAR, Shmuel COHEN
  • Isolated polypeptides of CD44 and uses thereof
    Patent number: 11560417
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: January 24, 2023
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen
  • ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF
    Publication number: 20200181234
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David NAOR, Lora ESHKAR-SEBBAN, Keren-Or AMAR, Shmuel COHEN
  • Isolated polypeptides of CD44 and uses thereof
    Patent number: 10611819
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 7, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen
  • ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF
    Publication number: 20170218045
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Application
    Filed: July 15, 2015
    Publication date: August 3, 2017
    Inventors: David NAOR, Lora ESHKAR-SEBBAN, Keren-Or AMAR, Shmuel COHEN